ABSTRACT Structural and functional analyses of myeloma immunoglobulins from inbred BALB/c mice and humans have provided important insights into the structure of the antibody molecule and the expression and evolution of antibody genes. One important question concerning these analyses is whether the myeloma process selects, in a nonrandom manner, the lymphocytes to be transformed. The availability of myeloma tumors in a second inbred strain of mouse, NZB, permits us to approach this question. In this respect, the NHrterminal amino acid sequences of 27-,light chains as well as data relating to the antigen-binding properties and immunoglobulin class distribution of NZB myeloma proteins are presented and compared with similar data from the BALB/c mouse. These studies suggest that the myeloma proteins from the BALB/c and NZB mice constitute two populations of immunoglobulins with distinct functional and structural properties. The implications of this observation are discussed.
Myeloma tumors may be artificially induced by injecting mineral oil into the peritoneal cavity of inbred BALB/c mice (1) . Chemical analysis of the homogeneous immunoglobulins derived from these myeloma tumors has provided important insights into the structure, genetics, and evolution of antibody molecules and genes (2, 3) . Moreoever, the observations that immunoglobulin variable regions can be divided into related sets or subgroups of sequences and that there are regions of extreme variability, termed "hypervariable regions," have placed important constraints on the modern theories of antibody diversity (4) . Indeed, our estimates as to the complexities of the various immunoglobulin gene families have been derived from the nature and extent of the heterogeneity seen in the corresponding myeloma proteins. Thus, it is important to determine whether the highly artificial process of myeloma induction provides a random sampling of lymphocyte diversity in the mouse. For example, if only 10% of the lymphocyte population were capable of being transformed by the myeloma process, then diversity estimates would be too low by a factor of 10. The availability of a second inbred mouse strain, NZB, in which myeloma tumors can be induced gave us an opportunity to examine this question.
It should be noted that three observations suggest that BALB/c myeloma proteins may represent only a selected subset of the antibody variable (V) regions. First, approximately 5-10% of the BALB/c myeloma proteins bind a restricted spectrum of simple haptens, including dinitrophenol, phosphorylcholine, and various simple carbohydrate moieties (5) . This frequency is much greater than would be expected from the frequency of lymphocytes binding the same haptens in normal individuals (6) . Accordingly, the BALB/c myeloma proteins appeartto represent a restricted sample of the potential functional repertoire of the BALB/c mouse. Second, nearly all
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of the BALB/c myeloma heavy chains screened thus far have unblocked NH2-terminal groups, whereas only about 20% of the serum heavy chains are unblocked (7) . The presence of blocked and unblocked NH2-terminal groups is indicative of different V subgroups (8) . Thus, the BALB/c myeloma proteins and serum immunoglobulins reflect different distributions of V subgroups and, presumably, different antibody specificities. Finally, when the residue alternatives at certain positions of myeloma sequences are compared to their counterparts from the normal serum pool, it is clear that some residues in the myeloma pool are not found in the normal pool (9) . Conversely, residue alternatives found in the normal pool are missing from the myeloma pool. These differences again suggest that the normal and myeloma pools of sequences express somewhat different subsets of the antibody repertoire. Selection also appears to operate at the level of myeloma constant regions. Indeed, two-thirds of BALB/c myeloma immunoglobulins are of the IgA class whereas less than 10% of the circulating immunoglobulins are of the IgA class (10) . Thus, there is evidence from both V and constant regions that the BALB/c myeloma proteins do not represent a random selection of normal serum antibody molecules.
The observation that myeloma tumors can be induced in a second inbred strain of mice, NZB, permits us to compare two populations of myeloma immunoglobulins induced within a single species, the mouse (11) . In this paper we report on the antigen-binding properties and immunoglobulin class distribution of NZB myeloma immunoglobulins as well as the NH2-terminal sequences from 27 K chains. These studies suggest that the myeloma proteins from the BALB/c and NZB mice constitute two populations of immunoglobulins with distinct functional and structural properties.
MATERIALS AND METHODS
Myeloma Tumors. The plasmacytomas used for these studies were induced in NZB/NIH mice.
Immunoglobulin Class Identification and Antigen-Binding Assays. The serological techniques for immunoglobulin class identification and the antigen-binding assays will be described elsewhere.
Immunoglobulin Production. 1 week prior to passage with 0.5 ml of pristane (2,6,10,14-tetramethylpentadecane; Aldrich). The ascites fluid from these mice was collected and pooled. Immunoglobulin Purification. The ascites fluids obtained from tumor-bearing mice were clarified by centrifugation at 15,000 X g for 10-18 min. An equal volume of phosphatebuffered saline (Pi/NaCl) with azide and EDTA (0.15 M NaCI/0.01 M P04/1 mM Na azide/1 mM EDTA, pH 7.4) was added and diluted 1:1 with a neutral solution of saturated ammonium sulfate. Volumes containing about 200 mg of protein were applied to Sephadex G-200 columns equilibrated Pi/ NaCl/azide/EDTA. Reduction/Alkylation. The peak corresponding to the myeloma protein was concentrated to 20 mg/ml and dialyzed against 0.15 M Tris*HCI, pH 8/0.15 M NaCl/2 mM EDTA, pH 7.0. Then, 0.01 vol of 1 M dithiotheitol was added and the solution was stirred at 37"C for 1.5 hr. The sample was then placed in an ice bath and 0.022 vol of 1 M iodoacetamide was added. The alkylation reaction was terminated by the addition of dithiothreitol to a molarity equal to that of the iodoacetamide added. The solution was dialyzed against 8 M urea in propionic acid for 2 hr.
Separation of Heavy and Light Chains. Reduced and alkylated proteins were fractionated on Sephadex G-150 columns equilibrated in urea/propionic acid. Pooled light chains were dialyzed against water and lyophilized.
Automated Sequence Analysis. The amino acid sequence analysis of the light chains was carried out on a Beckman 890A Sequencer using a dimethylbenzylamine program as described (12) (13) (14) . Briefly, aliquots of the phenylthiohydantoin derivatives of the amino acids were identified by gas chromatography and thin-layer chromatography. The amino acid derivatives were also hydrolyzed to free amino acids and analyzed on a Durrum D-500 amino acid analyzer as described (13) . A high-pressure liquid chromatography system (Waters Associates, Inc., Milford, MA) using a pH 4.27 buffer system (sodium acetate/water/ methanol) was used to identify the amino acid derivatives from some of the proteins. Generally, each protein was analyzed a single time. Repetitive yields ranged from 85-92%.
Mathematical Analyses. Fifty published NH2-terminal sequences of K chains from BALB/c mice were compared with the 27 NZB K chains presented in this paper. Mathematical techniques have been developed which allow us to ask several questions of these two populations of K sequences (15) . First, given one set of proteins (e.g., the BALB/c K chains), what is the likelihood that a second set of proteins (e.g., the NZB K chains) were drawn from the same population of sequences? Second, in quantitative terms, how much diversity exists within each population of sequences? These mathematical techniques can be summarized briefly as follows.
To determine whether the BALB/c and NZB sequences come from the same pool, one calculates a diversity distance index [D(B,N)] in which D is the diversity distance, B is the BALB/c sequences, and N is the NZB sequences. The diversity distance index is a measure of the similarity of the amino acid distributions in the two sets of sequences. The significance of the distance index is estimated by creating a statistical model that uses a randomly chosen second set of 27 BALB/c sequences drawn from the complete set of BALB/c sequences. Then one calculates the most likely distance [,u(B,27 )] this second set will have from the original BALB/c set and the standard deviation [6(3,27) ] of the distance index from ;t(B,27) if one repeats the random selection many times. Thus, to ask if BALB/c and NZB K chains are drawn from the same pool, one calculates the distance index D(B,N) and compares this to ,i(B,27) and b (B,27 (Fig. 1) . Nineteen of the VK sequences are distinct from one another, differing by as many as 13 residues.
By several criteria the diversity of NZB and BALB/c myeloma K chains is similar even though they appear to be drawn from distinct sets of proteins. (i) The distribution of variation in the first 23 residues is similar (Fig. 1) Criteria. The pools of NZB and BALB/c myeloma proteins differ from one another by three criteria: immunoglobulin lass distribution, antigen-binding properties, and amino acid sequence. (i) The expression of myeloma immunoglobulin classes in these two strains is quite distinct in that the distribution of NZB myeloma population assessed to date (t600 proteins) is 52% in the IgG class and 21% in the IgA class, whereas the distribution of the BALB/c myeloma population is 22% in the IgG class and 46% in the IgA class (unpublished data; see ref. 4 ). Thus, the myeloma process amplifies different ratios of immunoglobulin classes in these two inbred strains even though the same method of induction is used. (ii) The NZB myeloma proteins tend to bind different haptens than do-the BALB/c myeloma proteins (Table 2) . For example, it is striking that none of the NZB myeloma proteins, of >200 screened, bind dinitrophenol or phosphorylcholine, two of the most common haptens bound by BALB/c myeloma proteins. Indeed, 12 NZB myeloma proteins from those screened bind DNA (unpublished data), whereas few BALB/c proteins bind this antigen (19) . (ffi) The VK regions from the NZB and BALB/c myeloma proteins appear to form distinct populations of amino acid sequences.
The third supposition is supported by three observations. (i) The NH2-terminal 23 residues of 17 V sequences of NZB myeloma K chains have been examined (Fig. 1) . Nineteen different VK sequences are found among them and only 1 and three probably identical triplets appear (e.g., PC144, PC2419, and PC2454). In addition, the BALB/c sequences demonstrate at least 12 pairs of identical VK regions (9) . Thus, if the NZB and BALB/c myelomas were drawn from the same pool, one would expect more V sequences to be shared by the NZB and BALB/c myeloma K chains.
(ii) A relatedness analysis of the NZB and BALB/c K sequences also suggests that they constitute, at least in part, distinct populations. PC2316  PC3612   PC3609   PC3249   PC2200   PC118   PC39  PC920  PC938  PC144   PC2419  PC2454  PC613  PC674  PC2880  PC3741   PC1229  PC2155   PC2787   PC2205   PC2567  PC2954   PC3858  PC3936   PC2279   PC373   PC2426   5   10 15 20 (Fig. 2 ) may constitute structural gene polymorphisms. This hypothesis does not explain the distinct immunoglobulin class distribution in the myeloma proteins of these two strains, nor does it account for the observation that the myeloma proteins in the two strains bind distinct sets of antigens (Table 2) because a response to any of these haptens can be obtained in immunized animals from either strain.
An alternative and perhaps more likely explanation is that genetic differences outside the V genes lead to the expression of distinct populations of V genes in the lymphocytes of these strains. For example, the physiological differences in these two strains may lead to distinct internal antigenic environments, or distinct regulatory elements in the two strains may lead to the clonal expansion of (or induction of tolerance in) different sets of lymphocytes in the two strains. Hence, the myeloma process would transform distinct populations of lymphocytes in these two strains. This supposition is consistent with the observation that NZB but not BALB/c mice develop autoimmune disease with the concomitant expansion of clones of lymphocytes to self antigens (20) and that these antiself immunoglobulins are seen in the NZB but not the myeloma proteins. For example, 12 different NZB myeloma proteins bind DNA whereas few, if any, of their BALB/c counterparts do ( 4 and has been refined with additional data and computer searches for a tree with minimal branch lengths (see ref. 16 ).] Proc. Nati. Acad. Sci. USA 76 (1979) 1399 chemistry, by determining whether identical structural genes for individual K chains exist in both strains. The final answer may be that both models are partially correct.
Because Myeloma Proteins Appear to Represent Only a Subset of the Total Lymphocyte Repertoire That the Mouse Can Express, V Gene Counting from Myeloma Data Provide Only Minimal Estimates of Antibody Gene Diversity. There are several reasons for believing that the myeloma populations in BALB/c and NZB mice represent only a subset of the total immunoglobulin diversity these mice are capable of producing. (i) The antigen-binding spectra are quite distinct (Table 2) even though both strains can, by immunization, produce specificities not seen in the myeloma population. (ii) The normal pool of K chains has residue alternatives not seen in the myeloma pool and vice versa (9) . (iii) The VH subgroup distributions in the myeloma population and in normal immunoglobulins are quite distinct. Accordingly, the myeloma process provides a window through which we can glimpse the antibody repertoire, but the window probably views just a fraction of the total diversity. Because it is impossible to say how small this fraction is, it is difficult to estimate what fraction of the antibody repertoire is expressed by the myeloma process in each of the inbred strains. Estimates of the number of V subgroups in the antibody families, based on the sequence analysis of myeloma proteins, are therefore minimal estimates and could be far too low. Thus, the number of V genes in many antibody families may be substantially higher than previously estimated.
